

1 **Testing different forms of regulation of yolk thyroid hormone transfer in**
2 **pie flycatchers**

3

4 Tom Sarraude*^{1,2}, Bin-Yan Hsu¹, Ton G.G. Groothuis², Suvi Ruuskanen¹

5

6 ¹ Department of Biology, University of Turku, Turku, Finland

7 ² Groningen Institute for Evolutionary Life Sciences, University of Groningen,
8 Groningen, The Netherlands

9 * Corresponding author: Tom Sarraude, t.sarraude@rug.nl

10

11 **Running title: Regulation of yolk thyroid hormones transfer**

12

13 **Keywords:** maternal hormones; maternal effects; thyroid hormones; hormone transfer; birds

14

15 **Summary statement:** Thyroid hormones have been overlooked in the context of hormone-
16 mediated maternal effects. We found that mothers may regulate yolk thyroid hormone transfer
17 by regulating the conversion of the active form of the hormone.

18 **Abstract**

19 Hormones transferred from mothers to their offspring are considered a maternal tool to
20 prepare progeny for expected environmental conditions, increasing maternal fitness. To
21 flexibly influence offspring, mothers should be able to transmit the hormonal signals
22 independent of their own hormonal status. However, the ability to regulate hormone transfer
23 to the next generation is under debate. We studied the transfer of thyroid hormones (THs) to
24 eggs in a bird model. We elevated thyroxine (T_4 , the prohormone for the biological active
25 triiodothyronine, T_3) during egg-laying using T_4 implants on females of a wild population of
26 pied flycatchers (*Ficedula hypoleuca*), and measured plasma and yolk T_4 and T_3 as a
27 response. To our knowledge, studies that manipulated a prohormone and measured the change
28 in its active metabolites have rarely been conducted. We found an increase in plasma and yolk
29 T_4 and no change in T_3 concentrations leading to a similar decrease in yolk T_3/T_4 ratio in
30 response to the T_4 treatment in plasma and yolk. This suggests that mothers are able to
31 regulate the conversion of T_4 in T_3 to avoid potential costs of elevated exposure to the active
32 hormone to herself and to her progeny. Finally, contrary to our predictions, we found no
33 evidence of regulatory mechanisms at the follicle level, which is essential for independent
34 regulation of yolk hormone transfer.

35 **Introduction**

36 Maternal effects are the non-genetic influences of a mother on her progeny and are thought to
37 be adaptive (Moore et al., 2019; Mousseau and Fox, 1998; Yin et al., 2019). Maternal
38 hormones transferred to the next generation are a potential prenatal pathway for mothers to
39 shape their offspring phenotype (Groothuis et al., 2005; Groothuis et al., 2019; Ruuskanen
40 and Hsu, 2018, 20). Mothers transfer thyroid hormones (THs) that have so far received little
41 attention compared to glucocorticoids and androgens (Ruuskanen and Hsu, 2018). THs are
42 produced by the thyroid gland and are present in two main forms: thyroxine (T_4) and
43 triiodothyronine (T_3). T_4 , a precursor of T_3 , is converted to T_3 in tissues. T_3 has a much greater
44 affinity to TH receptors than T_4 . Thyroid hormones have pleiotropic effects that serve several
45 biologically important functions across vertebrates, including growth, reproduction and
46 metabolism (Ruuskanen and Hsu, 2018).

47 For maternal hormone transfer to be adaptive, mothers should be able to regulate their
48 deposition according to the expected environment during the offspring development.
49 Regulatory mechanisms of maternal hormone transfer are also essential to minimise
50 physiological trade-offs between optimal hormone exposure for the mother versus that for the
51 offspring (Groothuis and Schwabl, 2008). The evidence for a regulatory mechanism for
52 several hormones, including corticosterone and THs is mixed (Groothuis and Schwabl, 2008),
53 but such regulation could take place at the circulating level in the mothers and/or at the
54 follicle level. Regulation at the follicle level may happen by controlling the transfer or
55 conversion of THs or by producing THs independently from the thyroid gland. These
56 mechanisms have been suggested to exist in human ovaries (Monteleone et al., 2017; Rae et
57 al., 2007). If such regulatory mechanisms exist in other taxa, mothers may be able to regulate
58 the deposition of THs in their eggs independently from their own circulating TH levels. This
59 would free mothers from the possible constraint to optimise their own circulating levels of
60 THs and the levels in their eggs independently of each other. A few studies in birds have
61 shown some preliminary evidence that mothers may indeed be able to regulate yolk TH
62 transfer. In Japanese quails, a low-dose oral administration of T_4 resulted in an increase in
63 yolk T_3 but not in circulating T_3 , whereas T_4 increased in both tissues (Wilson and McNabb,
64 1997). Administration of T_3 in turn increased plasma T_3 but not yolk T_3 (Wilson and McNabb,
65 1997). Furthermore, artificial blocking of TH production in hens led to a decrease in yolk T_3
66 but not in plasma T_3 , while T_4 decreased in both tissues (Van Herck et al., 2013). These
67 studies on captive birds induced long exposure to elevated hormones and, importantly, do not

68 provide clear evidence for any of the regulatory mechanisms introduced above. Therefore,
69 there is a need for complementary studies under shorter time scales relevant for wild passerine
70 species.

71 In this experiment we tested whether mothers are able to regulate their transfer of yolk
72 THs, at the circulating and/or at the follicle level. We experimentally manipulated TH levels
73 with T₄ implants using a within-subject design in female pied flycatchers (*Ficedula*
74 *hypoleuca*) during egg-laying and collected plasma samples and pre- and post-implantation
75 eggs for the analysis of T₃ and T₄. Implanting the prohormone T₄ would enable us to test the
76 potential differential conversion of this hormone to the biological active T₃ in the mother as a
77 regulatory mechanism to protect the egg from increased exposure to these hormones. It would
78 also test whether mothers can regulate the transfer of hormones to the egg. First, if the implant
79 successfully increased circulating T₄, we would expect an increase in circulating T₃ as well
80 due to higher availability of the substrate (i.e. the prohormone T₄) and conversion to T₃.
81 Alternatively, females may buffer the increase in plasma T₄ by downregulating the conversion
82 of T₄ to T₃, thus yielding no increase in plasma T₃. Second, we predict that if mothers were
83 able to regulate yolk TH transfer independently from their circulating levels, only one of these
84 two compartments (i.e. plasma or yolk) would be affected by exogenous T₄, or one would be
85 more affected than the other (Groothuis and Schwabl, 2008). In this case, the T₃/T₄ ratio may
86 be different between the two tissues. Conversely, if mothers were unable to regulate yolk TH
87 transfer, one would expect both plasma and yolk THs to vary in the same direction and with a
88 similar magnitude in response to exogenous T₄ (Groothuis and Schwabl, 2008). Thus, the
89 T₃/T₄ ratio would not differ between the tissues.

90 **Material and methods**

91 The experiment was conducted in 2016 and 2017 in Turku, Finland (60°26'N, 22°10'E). The
92 study species, the pied flycatcher, generally lays a single clutch of 6 to 7 eggs. We inserted in
93 egg-laying females either a T₄ implant (10 µg, hereafter T4) or a control implant (hereafter
94 CO) (Innovative Research America, Sarasota, FL, USA). The amount of T₄ was aimed to
95 mimic natural T₄ production and was designed to release the hormone steadily over 21 days
96 (see below for more details on the dose and implantation).

97 ***Preparation of T₄ implants and implantation***

98 Two types of sterile T₄ implants (ca. 3 mm of diameter) were used for this experiment: ready-
99 made T₄ pellets (10 µg, hereafter PT4) and respective controls (PCO) which were identical,

100 but without T₄. Both implants were produced by Innovative Research America (Sarasota, FL,
101 USA). The amount of T₄ in the implants was based on the production rate of T₄ measured in
102 chickens, quail and pigeons (1–3 µg T₄/100 g of body weight per day (McNabb and Darras,
103 2015) and adjusted to the average body mass of pied flycatchers. T₄ is embedded in a matrix
104 that is designed to steadily release the hormone for 21 days.

105 Before implantation between the scapula, the skin was disinfected with a cotton pad
106 dipped in 70% ethanol. An incision was made with a 18G needle (BD Microlance™) and the
107 implant was inserted and pushed away from the incision to avoid losing the implant. The
108 wound was sealed with veterinary tissue adhesive 3M Vetbond™, commonly used in
109 experiments with pit tags and shown to have no effects on birds.

110 *Experimental design - captive females*

111 First, to validate that implants increased circulating THs in a short time window after
112 implantation, we conducted an experiment with female pied flycatchers in captivity. Since the
113 yolk formation takes approximately 3.5 to 4 days in passerines (Williams, 2012), implants
114 inserted during egg-laying need to increase hormone levels within days to be able to quantify
115 their effect on newly formed eggs. Captive birds (on natural photoperiod and ad libitum food)
116 were used for the validation experiment as repeated disturbance during egg-laying in the wild
117 population could have caused nest desertion. On the 4th day after capture, each female
118 received either a subcutaneous control or T₄ implant (n = 4 per group). Blood samples were
119 taken before the implant was inserted, 24 hours and 72 hours after the implant (between
120 09.30-11.30 a.m.). Circulating TH levels in response to the implants are presented in Table 1.

121 *Experimental design - wild females*

122 The first egg of a clutch was collected and replaced by a dummy egg as a within-clutch
123 control (hereafter “pre-implant”). On the morning of the second egg (7–9 a.m.), females were
124 captured and received a T₄ or a control implant as above. The last egg of a clutch (mean egg
125 rank (SD) = 6 (0.25), hereafter “post-implant”) was collected, as it is mostly formed under the
126 influence of the hormone implant (see above). Early in the incubation, on average 1.3 days
127 (SD = 1.0) after the last egg laid, females were blood sampled for the analysis of circulating
128 T₄ and T₃.

129 *Hormone analysis*

130 Blood samples (ca. 40 µl) were taken from the brachial vein. Plasma was collected via

131 centrifuging and frozen at -20°C until analysis. Eggs were thawed, yolks separated,
132 homogenised in MilliQ water (1:1) and a small sample (ca. 50 mg) was used for TH analysis.
133 Yolk and plasma THs were analysed using nano-LC-MS/MS, following Ruuskanen et al.
134 (2018; 2019). TH concentrations, corrected for extraction efficiency, are expressed as pg/mg
135 yolk or pg/ml plasma.

136 *Statistical analysis*

137 Data were analysed with the software R version 3.6.2 (R Core Team, 2020). Linear mixed
138 models (LMMs) were fitted using the R package *lme4* (Bates et al., 2015). P-values were
139 obtained by model comparison using Kenward-Roger approximation from the package
140 *pbkrtest* (Halekoh and Højsgaard, 2014). Estimated marginal means and standard errors
141 (EMMs \pm SE) were derived from models using the package *emmeans* (Lenth, 2019). Effect
142 size estimates (Cohen's *d*) obtained from marginal means were computed with the package
143 *emmeans*. Effect size estimates obtained from the raw data were calculated with the package
144 *effsize* (Torchiano, 2020). Model residuals were checked for normality and homogeneity by
145 visual inspection.

146 Yolk THs were log-transformed to achieve normal distribution of the residuals. Yolk
147 TH concentrations and T_3/T_4 ratio were analysed by fitting linear mixed models that included
148 the treatment (i.e., T_4 or CO implant) as the predictor, hormone levels in the pre-implant egg
149 and year as covariates, and the hormone assay as a random intercept.

150 Plasma TH levels of the incubating females were analysed using linear regressions
151 with the type of implant as a fixed factor and body mass, ambient temperature and time of the
152 day as covariates, as these covariates are known to influence circulating levels (McNabb and
153 Darras, 2015). Covariates were centred and scaled. Year was not included in the model as it
154 covaried with ambient temperature ($\text{VIF} > 2$), and the latter is known to affect circulating THs
155 (McNabb and Darras, 2015).

156 Effect sizes (Cohen's *d*) of the treatment on yolk and wild female plasma THs were
157 estimated from marginal means. Effect size estimates of the treatment on the T_3/T_4 ratio in the
158 yolk and in captive female plasma were computed from the raw data. To avoid nest
159 abandonment, we did not blood sample wild females during egg laying. Therefore, we used
160 the data from captive birds in the following way: Plasma samples from captive females
161 averaged over day 1 and 3 after the implantation (reflecting the yolking phase of the last egg
162 in wild birds) were compared with the post-implant last eggs collected from wild females.

163 **Ethical note**

164 The experiments were conducted under licenses from the Animal Experiment Board of the
165 Administrative Agency of South Finland (ESAVI1018/04.10.07/2016) and South-Western
166 Finland Centre for Economic Development, Transport and Environment
167 (VARELY/412/2016).

168 **Results**

169 Yolk THs of pre-implant eggs (first eggs of a clutch) did not differ between females with CO
170 or T₄ implants (mean yolk T₄ (SE), CO = 8.29 (0.61) vs T₄ = 7.63 (0.43); mean yolk T₃ (SE),
171 CO = 2.85 (0.20) vs T₄ = 2.94 (0.38); all $t \leq 0.89$ and all $p \geq 0.39$). After receiving a T₄
172 implant, females produced eggs with ca. two times higher yolk T₄ concentration than CO-
173 implanted females (Estimated marginal means, EMMs \pm SE: post-implant treated egg = 17.14
174 \pm 2.07 pg/mg yolk vs post-implant control egg = 8.54 \pm 1.08 pg/mg yolk, Table 2, Figs. 1A,
175 2A). However, post-implant yolk T₃ did not differ between the groups (mean (SE), CO = 2.34
176 (0.27) vs T₄ = 2.72 (0.29); Table 2, Figs. 1B, 2A).

177 Regarding circulating THs, captive females implanted with a T₄ implant had higher
178 circulating T₄ than captive control females during the first 3 days after the implant (Table 1).
179 There was a similar, but non-significant, trend in wild female plasma T₄ early in the
180 incubation (when egg laying was finished, so about 10 days after implantation) (Table 2).
181 Plasma T₃ was not affected by the implants (Tables 1, 2).

182 The treatment decreased the T₃/T₄ ratio in the post-implant egg (Table 2) and the trend
183 was similar for plasma levels (Fig. 2B), and a visual inspection of the effect sizes for T₃/T₄
184 ratios showed no difference between the two tissues (Fig. 2B).

185 **Discussion**

186 To our knowledge, this study is the first one to manipulate circulating thyroid hormones (THs)
187 of a wild bird species during egg-laying, to study potential regulation of maternal TH transfer
188 at the level of mothers' circulation and at the follicle level. Contrary to previous studies on
189 other maternal hormones (e.g. steroid hormones), we not only looked at the response in the
190 implanted hormone T₄, but also at its active metabolite T₃. We found an increase in plasma
191 and yolk T₄ in response to exogenous T₄ but not in T₃, while the T₃/T₄ ratio did not appear to
192 differ between the tissues. This result would indicate an absence of regulation of transfer of
193 these two hormones from mothers to eggs (supporting the epiphenomenon hypothesis in
194 Groothuis and Schwabl (2008). We predicted that elevated plasma T₄ would increase plasma

195 or yolk T₃, the more potent hormone, because of the increased amount of its precursor, T₄.
196 However, we observed no changes in circulating or yolk T₃. This result, together with the
197 rapid decrease in plasma T₄ after implantation observed in captive females, suggest a change
198 in the peripheral TH metabolism to quickly remove excess T₄. In rats, hyperthyroidism
199 increases the conversion of T₄ and T₃ into inactive metabolites (Bianco et al., 2002).
200 Likewise, increased circulating T₄ rapidly decreases the conversion of T₄ into T₃ (Bianco et
201 al., 2002). Both mechanisms prevent the production of T₃, which may explain why we
202 observed no increase in plasma T₃. These mechanisms may allow individuals to cope with
203 elevated THs and could be important tools for mothers to protect themselves and their
204 progeny from the potentially detrimental consequences of elevated T₃. To ascertain this
205 hypothesis, one should analyse the expression and activity of different enzymes involved in
206 TH metabolism in response to exogenous THs, both in mothers and in embryos.

207 In addition to regulating their own plasma levels of THs, we hypothesised that mothers
208 may be able to regulate the exposure of the developing follicles to THs. We found no evidence
209 for such regulatory mechanism, as the T₃/T₄ ratio appeared not to differ between female
210 plasma and yolk. This result is contrary to that of Wilson and McNabb (Wilson and McNabb,
211 1997), where yolk T₃, but not circulating T₃ was increased in response to long-term T₄
212 administration. This contradiction may be caused by different time scales between the two
213 studies. In our study, the peak in T₄ rapidly decreased after implantation. Conversely, Wilson
214 and McNabb administrated exogenous T₄ for longer periods of time, which might have forced
215 females to deposit T₃ in their eggs to maintain normal plasma T₃.

216 We found that females regulated the concentrations of plasma T₄ and T₃ but not TH
217 transfer to the yolk. Whether the first regulatory mechanism has been selected to benefit the
218 mother or the offspring is yet unclear. This could be tested by elevating plasma and yolk T₃
219 and measuring whether potential detrimental effects are larger in the mother or the offspring.
220 Besides, further studies could also aim at investigating the changes in thyroid hormone
221 metabolism (enzyme production and activity) in response to increased hormones.

Acknowledgements

We thank Sophie Michon and Florine Ceccantini for her help on the field. Mass spectrometry were performed at the Turku Proteomics Facility, University of Turku, supported by Biocenter Finland.

Competing interests

We have no competing interest.

Funding

The study was funded by the Academy of Finland (grant no. 286278 to SR), the Finnish National Agency for Education (grant no. TM-15-9960 to TS), the Societas pro Fauna et Flora Fennica (grant to TS) and the University of Groningen (grant to TG).

Data accessibility

Data have been deposited on the online repository Zenodo. DOI: 10.5281/zenodo.3747401

Authors' contribution

TS and SR designed the study and collected the data. TS analysed the data and wrote the first draft of the manuscript. SR analysed TH concentrations. All authors edited the manuscript and approved its final version.

References

- Bates, D., Mächler, M., Bolker, B. and Walker, S.** (2015). Fitting Linear Mixed-Effects Models Using lme4. *J. Stat. Softw.* **67**, 1–48.
- Bianco, A. C., Salvatore, D., Gereben, B. Z., Berry, M. J. and Larsen, P. R.** (2002). Biochemistry, Cellular and Molecular Biology, and Physiological Roles of the Iodothyronine Selenodeiodinases. *Endocr. Rev.* **23**, 38–89.
- Groothuis, T. G. G. and Schwabl, H.** (2008). Hormone-mediated maternal effects in birds: mechanisms matter but what do we know of them? *Philos. Trans. R. Soc. B Biol. Sci.* **363**, 1647–1661.
- Groothuis, T. G. G., Müller, W., von Engelhardt, N., Carere, C. and Eising, C.** (2005). Maternal hormones as a tool to adjust offspring phenotype in avian species. *Neurosci. Biobehav. Rev.* **29**, 329–352.
- Groothuis, T. G. G., Hsu, B.-Y., Kumar, N. and Tschirren, B.** (2019). Revisiting mechanisms and functions of prenatal hormone-mediated maternal effects using avian species as a model. *Philos. Trans. R. Soc. B Biol. Sci.* **374**, 20180115.
- Halekoh, U. and Højsgaard, S.** (2014). A Kenward-Roger Approximation and Parametric Bootstrap Methods for Tests in Linear Mixed Models - The R Package **pbrktest**. *J. Stat. Softw.* **59**, 1–32.
- Lenth, R.** (2019). emmeans: Estimated Marginal Means, aka Least-Squares Means. R package version 1.3.2.
- McNabb, F. M. A. and Darras, V. M.** (2015). Thyroids. In *Sturkie's Avian Physiology (Sixth Edition)*, pp. 535–547. London: Elsevier.
- Monteleone, P., Faviana, P. and Artini, P. G.** (2017). Thyroid peroxidase identified in human granulosa cells: another piece to the thyroid-ovary puzzle? *Gynecol. Endocrinol.* **33**, 574–576.
- Moore, M. P., Whiteman, H. H. and Martin, R. A.** (2019). A mother's legacy: the strength of maternal effects in animal populations. *Ecol. Lett.* **22**, 1620–1628.
- Mousseau, T. A. and Fox, C. W.** (1998). The adaptive significance of maternal effects. *Trends Ecol. Evol.* **13**, 403–407.
- R Core Team** (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
- Rae, M. T., Gubbay, O., Kostogiannou, A., Price, D., Critchley, H. O. D. and Hillier, S. G.** (2007). Thyroid Hormone Signaling in Human Ovarian Surface Epithelial Cells. *J. Clin. Endocrinol. Metab.* **92**, 322–327.
- Ruuskanen, S. and Hsu, B.-Y.** (2018). Maternal Thyroid Hormones: An Unexplored Mechanism Underlying Maternal Effects in an Ecological Framework. *Physiol. Biochem. Zool.* **91**, 904–916.

- Ruuskanen, S., Hsu, B.-Y., Heinonen, A., Vainio, M., Darras, V. M., Sarraude, T. and Rokka, A.** (2018). A new method for measuring thyroid hormones using nano-LC-MS/MS. *J. Chromatogr. B* **1093–1094**, 24–30.
- Ruuskanen, S., Espín, S., Sánchez-Virosta, P., Sarraude, T., Hsu, B.-Y., Pajunen, P., Costa, R. A., Eens, M., Hargitai, R., Török, J., et al.** (2019). Transgenerational endocrine disruption: Does elemental pollution affect egg or nestling thyroid hormone levels in a wild songbird? *Environ. Pollut.* **247**, 725–735.
- Torchiano, M.** (2020). *effsize: Efficient Effect Size Computation*. R package version 0.7.8.
- Van Herck, S. L. J., Geysens, S., Bald, E., Chwatko, G., Delezie, E., Dianati, E., Ahmed, R. G. and Darras, V. M.** (2013). Maternal transfer of methimazole and effects on thyroid hormone availability in embryonic tissues. *J. Endocrinol.* **218**, 105–115.
- Williams, T. D.** (2012). *Physiological adaptations for breeding in birds*. Princeton, NJ: Princeton University Press.
- Wilson, C. M. and McNabb, F. M. A.** (1997). Maternal Thyroid Hormones in Japanese Quail Eggs and Their Influence on Embryonic Development. *Gen. Comp. Endocrinol.* **107**, 153–165.
- Yin, J., Zhou, M., Lin, Z., Li, Q. Q. and Zhang, Y.** (2019). Transgenerational effects benefit offspring across diverse environments: a meta-analysis in plants and animals. *Ecol. Lett.* **22**, 1976–1986.

Tables

Table 1: Circulating T₄ and T₃ in captive female pied flycatchers in response to T₄ (T4) or control (CO) implants. Females were sampled prior to insertion of the implant, 24h and 72h later.

| Implant | CO | | | T4 | | |
|---------------------------|--------------|--------------|--------------|--------------|----------------|--------------|
| Hour | 0 | 24 | 72 | 0 | 24 | 72 |
| N | 3 | 4 | 4 | 3 | 3 | 3 |
| Mean (SD) | | | | | | |
| T ₄ (in pg/μl) | 4.9 (1.7) | 3.5 (1.3) | 4.9 (1.9) | 5.3 (2.6) | 28.9 (18.0) | 8.4 (3.3) |
| Mean (SD) | | | | | | |
| T ₃ (in pg/μl) | 0.7 (0.5) | 0.5 (0.4) | 0.9 (0.5) | 0.7 (0.1) | 0.7 (0.2) | 1.1 (0.2) |

Table 2: (a) Full linear mixed models of yolk THs in response to T₄ implants, in pied flycatchers (sample sizes: T₄ = 13 eggs; CO = 11 eggs). Hormone assay was included as a random intercept. (b) Full linear models of plasma THs in response to T₄ implants (sample sizes; T₄ = 11 females; CO = 10 females). Covariates were centred and scaled. Ndf = 1. Significant p values are shown in bold.

| (a) | Estimate (SE) | F_{ddf} | P value |
|--|---------------|-----------------------|--------------|
| Yolk T₄ | | | |
| Implant (T ₄) | 0.75 (0.19) | 14.96 _{17.6} | 0.001 |
| Pre-implant egg | 0.07 (0.06) | 1.09 _{20.0} | 0.31 |
| Year (2017) | 0.09 (0.20) | 0.18 _{18.2} | 0.67 |
| Yolk T₃ | | | |
| Implant (T ₄) | 0.12 (0.11) | 1.09 _{17.1} | 0.31 |
| Pre-implant egg | 0.20 (0.05) | 13.33 _{18.1} | 0.002 |
| Year (2017) | -0.01 (0.12) | 0.01 _{17.8} | 0.92 |
| T₃/T₄ ratio | | | |
| Implant (T ₄) | -0.12 (0.03) | 12.28 _{17.6} | 0.003 |
| Pre-implant egg | -0.01 (0.11) | 0.01 _{19.3} | 0.91 |
| Year (2017) | -0.01 (0.03) | 0.10 _{18.2} | 0.76 |
| (b) | Estimate (SE) | t | P value |
| Plasma T₄ | | | |
| Implant (T ₄) | 1.16 (0.75) | 1.54 | 0.14 |
| Body mass | -0.90 (0.38) | -2.33 | 0.03 |
| Temperature | 0.11 (0.39) | 0.29 | 0.78 |
| Time | -0.46 (0.39) | -1.80 | 0.26 |
| Plasma T₃ | | | |
| Implant (T ₄) | 0.14 (0.15) | 0.95 | 0.36 |
| Body mass | -0.02 (0.08) | -0.26 | 0.80 |
| Temperature | -0.05 (0.08) | -0.26 | 0.58 |
| Time | -0.09 (0.08) | -1.16 | 0.26 |

Figures




Figure 1: Concentrations of T₄ (A) and T₃ (B) in eggs of female pied flycatchers implanted with a control implant (CO implant), or 10 µg T₄ implant (T4 implant). “Before” and “after” respectively refer to eggs collected before or after the females had received an implant.




Figure 2: (A) Cohen's *d* and 95% C.I.s for yolk (post-implant egg) and plasma (wild females) T₃ and T₄ calculated from the marginal means of the respective models. (B) Cohen's *d* and 95% C.I.s for the T₃/T₄ ratio in the yolk (post-implant egg) and plasma (captive females) calculated from the raw data.